RSS

Entresto

Novartis has established FortiHFy, a global clinical programme, to generate additional data on the effects of the company’s novel heart failure medicine, Entrestro more

News

The heart failure market is set to rise by £5.8bn ($8.6bn) within the next century, according to GlobalData more

News

Novartis’ Entresto has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of heart failure more

News

The European Commission (EC) has approved Novartis’ Entresto (sacubitril/valsartan) for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) more

News